Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Assets (2019 - 2025)

Historic Assets for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $265.5 million.

  • C4 Therapeutics' Assets fell 2940.28% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 1963.7%. This contributed to the annual value of $349.6 million for FY2024, which is 713.21% down from last year.
  • C4 Therapeutics' Assets amounted to $265.5 million in Q3 2025, which was down 2940.28% from $296.5 million recorded in Q2 2025.
  • C4 Therapeutics' Assets' 5-year high stood at $528.4 million during Q2 2021, with a 5-year trough of $265.5 million in Q3 2025.
  • Its 5-year average for Assets is $404.4 million, with a median of $381.1 million in 2024.
  • Its Assets has fluctuated over the past 5 years, first surged by 12167.23% in 2021, then tumbled by 2940.28% in 2025.
  • Over the past 5 years, C4 Therapeutics' Assets (Quarter) stood at $506.8 million in 2021, then fell by 14.98% to $430.8 million in 2022, then dropped by 12.62% to $376.5 million in 2023, then decreased by 7.13% to $349.6 million in 2024, then dropped by 24.06% to $265.5 million in 2025.
  • Its last three reported values are $265.5 million in Q3 2025, $296.5 million for Q2 2025, and $319.5 million during Q1 2025.